Country: Canada
Language: English
Source: Health Canada
ALISKIREN (ALISKIREN FUMARATE)
SANDOZ CANADA INCORPORATED
C09XA02
ALISKIREN
300MG
TABLET
ALISKIREN (ALISKIREN FUMARATE) 300MG
ORAL
28
Prescription
RENIN INHIBITORS
Active ingredient group (AIG) number: 0152352002; AHFS:
CANCELLED PRE MARKET
2017-12-06
_ _ _Sandoz Aliskiren Page 1 of 28_ PRODUCT MONOGRAPH PR SANDOZ ALISKIREN aliskiren (as aliskiren fumarate) Tablets, 150 and 300 mg Renin inhibitor Sandoz Canada Inc. 145 Jules-Léger Boucherville (QC) J4B 7K8 Date of Revision: August 31, 2016 Submission Control No: 197205 _ _ _Sandoz Aliskiren Page 2 of 28_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................... 4 ADVERSE REACTIONS ................................................................................................. 8 DRUG INTERACTIONS ................................................................................................ 12 DOSAGE AND ADMINISTRATION ........................................................................... 15 OVERDOSAGE ............................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 16 STORAGE AND STABILITY ....................................................................................... 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................ 19 PART II: SCIENTIFIC INFORMATION ............................................................................... 20 PHARMACEUTICAL INFORMATION ..................................................................... 20 CLINICAL TRIALS ....................................................................................................... 21 DETAILED PHARMACOLOGY ........................................................................ Read the complete document